Haemonetics Corporation (HAE) - 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2007
Business Overview: Haemonetics is a market leader in automated blood processing technology, manufacturing systems and single-use consumables for blood donation, processing, and surgical salvage. The company operates as a single segment with three product families: Donor (plasma, blood bank, red cell), Patient (surgical blood salvage), and Software/Services. Operations are global, with approximately 57% of revenue generated outside the United States.
Key Financial Metrics (Fiscal Year 2007)
| Metric | 2007 (in thousands) | 2006 (in thousands) | Change |
|---|---|---|---|
| Net Revenues | $449,607 | $419,733 | +7.1% |
| Gross Profit | $227,300 | $220,535 | +3.1% |
| Gross Margin | 50.6% | 52.5% | -1.9 pts |
| Operating Income | $62,745 | $98,338 | -36.2% |
| Net Income | $49,109 | $68,396 | -28.2% |
| Diluted EPS | $1.78 | $2.49 | -28.5% |
| Cash & Equivalents | $229,227 | $250,667 | -8.5% |
| Total Debt | $28,876 | $39,153 | -26.2% |
| Working Capital | $321,654 | $330,288 | -2.6% |
| Current Ratio | 4.9 | 4.7 | + |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 7.1% driven by a 7.2% increase in disposable sales (87.6% of total revenue) and a 25.4% increase in software and service revenue. This growth was partially offset by a 13.7% decline in equipment sales and unfavorable foreign exchange impacts (-0.4%).
- Profitability Decline: Operating income decreased 36.2% and Net Income decreased 28.2%. This decline is largely attributable to non-recurring items in the prior year and new expenses in the current year:
- 2006 Comparison: Fiscal 2006 included a $26.4 million arbitration award income from Baxter, which significantly inflated prior-year operating income.
- 2007 Expenses: Fiscal 2007 included a $9.1 million charge for in-process research and development (IPR&D) related to the Arryx acquisition, $10.2 million in stock-based compensation expense (due to SFAS 123(R) adoption), and $3.5 million in restructuring costs.
- Acquisitions: The company acquired Arryx, Inc. (nanotechnology) for $23.2 million and Information Data Management (IDM) for approximately $9 million to expand R&D and software capabilities.
- Legal Settlement: The company received a $6.0 million settlement from Baxter regarding platelet pathogen reduction contracts, recorded as income in Q4 2007.
Guidance, Outlook, and Risks
- Outlook: Management expects the reported tax rate for fiscal 2008 to be approximately 33.5% to 34.5%. The company is executing a business transformation focused on international operations to complement U.S. growth.
- Share Repurchases: The company completed a $40 million share repurchase program in late 2006 and announced a new $75 million repurchase program commencing May 2, 2007.
- Restructuring: A subsequent event noted plans to consolidate European customer support functions, expecting $4-5 million in exit costs and $1.5 million in annual operating savings.
- Key Risks:
- Customer Concentration: The Japanese Red Cross Society accounted for 15.8% of net revenues in 2007. A reduction in their purchases would significantly impact revenue.
- Foreign Exchange: Approximately 57% of revenue is generated in foreign currencies (primarily Yen and Euro). A strengthening U.S. dollar adversely affects reported results.
- Regulatory: Products are subject to strict FDA and international regulations; delays in approvals or adverse regulatory actions could impact operations.
- Competition: Intense competition exists in plasma, platelet, and red cell collection markets, particularly from Fenwal (formerly Baxter) and Gambro BCT.
Investor Verification Checklist
- Recurring vs. Non-Recurring Income: Verify the sustainability of operating margins by excluding the $26.4M Baxter arbitration award from 2006 and the $9.1M IPR&D charge from 2007 to assess core operational performance.
- Japanese Red Cross Exposure: Monitor the stability of the relationship with the Japanese Red Cross, which represents nearly 16% of total revenue.
- Foreign Exchange Hedging: Review the effectiveness of the company's forward contract hedging strategy against the strengthening U.S. dollar, which negatively impacted 2007 results.
- Acquisition Integration: Assess the progress and financial contribution of the Arryx and IDM acquisitions, particularly given the significant IPR&D write-off associated with Arryx.
- Stock-Based Compensation: Note the impact of the new $10.2 million stock-based compensation expense due to SFAS 123(R) adoption, which will be a recurring cost in future periods.